¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"multiple cone method"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • auscultatory method
    ûÁø¹ý
  • acquisition method
    ȹµæ¹æ¹ý
  • activated sludge method
    Ȱ¼ºÇذ¨¸ð·¡¹ý, Ȱ¼º¿À´Ï¹ý
  • actuarial method
    º¸ÇèÅë°è¹ý
  • agar diffusion method
    ¿ì¹«È®»ê¹ý
  • alkali denaturation method
    ¾ËÄ®¸®º¯¼º¹ý
  • allochromatic method
    º¯»ö¹ý
  • alternate paired case method
    ±³´ë´ë¸³È¯ÀÚ¿ä¹ý
  • analytical method
    ºÐ¼®¹ý
  • bioassay method
    »ý¹°ÇÐÀû°ËÁ¤¹ý
  • bisecting method
    À̵îºÐ¸é¹ý
  • Black method
    ºí·¢¹æ¹ý
  • blind method
    ´«°¡¸²¹ý
  • bolus-tracking method
    µ¢¾î¸®ÃßÀû¹æ¹ý
  • brine flotation method
    ½Ä¿°¼öºÎÀ¯¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • multiple subpial transection
    ´Ù¹ß¿¬¸·¹ØÀý´Ü¼ú
  • multiple suture synostosis
    ´Ù¹ßºÀÇÕÀ¯ÂøÁõ
  • acquisition method
    ȹµæ¹æ¹ý
  • activated sludge method
    Ȱ¼ºÇذ¨¸ð·¡¹ý, Ȱ¼º¿À´Ï¹ý
  • actuarial method
    º¸ÇèÅë°è¹ý
  • agar diffusion method
    ¿ì¹«È®»ê¹ý
  • agar filtration method
    ¿ì¹«°Å¸£±â¹ý, ¿ì¹«¿©°ú¹ý
  • agar layer method
    ¿ì¹«ÁßÃþ¹ý
  • agar streak method
    ¿ì¹«È­¼±¹ý
  • alkali denaturation method
    ¾ËÄ®¸®º¯¼º¹ý
  • allochromatic method
    º¯»ö¹ý
  • alternate paired case method
    ±³´ë´ë¸³È¯ÀÚ¿ä¹ý
  • analytical method
    ºÐ¼®¹ý
  • ascending method
    »ó½Â¹ý
  • aspirative irrigation method
    ÈíÀμ¼Ã´¹ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • agar streak method
    ÇÑõȭ¼±¹ý(¡­ûþàÊÛö).
  • albumin method
    ¾ËºÎ¹Î¹ý
  • allochromatic method
    º¯»ö¹ý.
  • alternate case method
    ±³´ëȯÀÚ¿ä¹ý.
  • alternate paired case method
    ±³´ë´ë¸³È¯ÀÚ¿ä¹ý(ÎßÓÛÓßí¡ü´íºèþÛö).
  • analytical method
    ºÐ¼®¹ý
  • gasometric method
    °¡½ºÁ¤·®¹ý.
  • gradient method
    °è´ÜÀû°Ë»ç¹ý
  • graphic method
    ±×·¡ÇÁ¹ý, ¼±µµ¹ý(ËÛËÀËÑ).
  • gravimetric method
    Áß·®¹ý(ñìÕáÛö).
  • hanging drop method
    ÇöÀû¹ý(úØîÙÛö).
  • hemiglobincyanide <= cyanmethemoglobin> method
    ½Ã¾ÈÇì¹Ì±Û·Îºó¹ý<½Ã¾È¸ÞÆ®Çì¸ð±Û·Îºó¹ý>
  • high flow method
    °íÀ¯·®¹ý(ÍÔêüåÖÛö).
  • homozygous typing method
    µ¿ÇüÁ¢ÇÕ¼º Çüº°ÆÇº°¹ý
  • hypobromite method
    ÇÏÀÌÆ÷ºê·Ò»ê¿°¹ý.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • multiple allelomorph
    º¹´ë¸³À¯ÀüÀÚ(¡­Óßí¡ë¶îîí­).
  • multiple allelomorphism
    º¹´ë¸³¼º(¡­Óßí¡àõ).
  • multiple amputation
    ´ÙºÎÀ§ Àý´Ü(ÒýÝ»êÈôîÓ¨).
  • multiple angiofibroma
    ´Ù¹ß¼º Ç÷°ü ¼¶À¯Á¾
  • multiple benign cystic epithelioma
    ´Ù¹ß¼º ¾ç¼º ³¶Á¾¼º »óÇÇÁ¾
  • multiple birth
    ´Ù»ê(Òýß§), ´ÙÅÂÃâ»ê(Òý÷Ãõóß§).
  • multiple bond
    ´ÙÁß°áÇÕ(ÒýñìÌ¿ùê).
  • multiple budding
    ´Ù¼öÃâ¾Æ(Òýâ¦õóä´).
  • multiple budding
    ´Ù¼öÃâ¾Æ(Òýâ¦õóä´).
  • multiple cerebral sclerosis
    ¹æ»ç ´Ù¹ß¼º ´ë³ú°æÈ­Áõ(ÒýÛ¡àõÓÞÒàÌãûùñø).
  • multiple cerebral sclerosis
    ´Ù¹ß¼º ´ë³ú°æÈ­Áõ(Û¯ÞÒ¡­ÓÞÒàÌãûùñø)
  • multiple chain
    º¹½Ä(ÜÜãÒ)»ç½½.
  • multiple characters
  • multiple compressed tablet
    ´ÙÁß¾ÐÃàÁ¤Á¦(Òýñìäâõêïüð¥).
  • multiple congenital polyposis
    ´Ù¹ß¼º ¼±Ãµ¼º(¡­à»ô¸àõ) Æú¸³Áõ(¡­ñø)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • pattern method
    ÆäÅϹý(Ûö)
  • PER method
    PER¹ý(Ûö)
  • pH jump method
    pH ±Þº¯¹ý(ÐáܨÛö)
  • phosphite-triester method
    Æ÷½ºÆÄÀÌÆ®-»ï(ß²)¿¡½ºÅ͹ý(Ûö)
  • plaque reduction method
    ÇöóÅ© °¨¼Ò¹ý(Êõá´Ûö)
  • plus-minus method
    °¡°¨¹ý(Ê¥ÊõÛö)
  • porous disk method
    ´Ù°ø¼º(ÒýÍöàõ) ¿ø¹Ý¹ý(ê«ÚïÛö)
  • potential-drop method
    ÀüÀ§ °­ÇϹý(ï³êÈ˽ù»Ûö)
  • powder method
    ºÐ¸»¹ý(ÝÏØÇÛö)
  • preparative method
    Á¦Á¶¹ý(ð²ðãÛö)
  • pressure-jump method
    ¾Ð·Â(äâÕô)-¶Ù±â¹ý(Ûö)
  • primed synthesis method
    ±âÆø ÇÕ¼º¹ý(ÑÃøïùêà÷Ûö)
  • protein efficiency ratio method
    ´Ü¹éÁú(Ó±ÛÜòõ) È¿À²ºñ¹ý(üù×ËÝïÛö)
  • pulse-height shift method
    "ÆÞ½º ³ôÀÌ À̵¿(ì¹ÔÑ, ¿Å±è)¹ý(Ûö)"
  • Ramon method
    ¶ó¸¸¹ý(Ûö)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CPRAM controlled partial rebreathing anesthesia method
DBCL dilute blood clot lysis [method]
DEALE declining exponential approximation of life expectancy [method]
3DFEM three-dimensional finite element method
EPSEM equal probability of selection method
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
HME Hereditary Multiple Exostoses
MAACL Multiple Affect Adjective Check List
MANOVA Multiple Analysis of Variance
MAR Multiple Antibiotic Resistance
MAP Multiple Antigen Peptide
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Barker's method
    ¹Ù¾ÆÄ¿¹ý
    Ƽ¿À½Ã¾È¿°°ú Á¦ 2Áú»ê öÀÇ È­ÇÕ¿¡ ÀÇÇÑ ºñ»ö¹ý.
  • bioassay method
    »ý¹°ÇÐÀû °ËÁ¤¹ý
  • candle jar method
    Ä­µé Àھƹý, Ä­µé ÀÚ¾Æ ¹è¾ç¹ý
  • carbol fuchsin method
    Ä«¸£º¼ Ǫũ½Å ¹ý
  • Charter's method
    Â÷ÅÍ ¹ý
    Ä©¼Ö »ç¿ë¹ýÀÇ Çϳª·Î, ¼ÖÀÌ Ä¡¾Æ¿Í Ä¡Àº¿¡ ´ëÇÏ¿© 45¡Æ·Î Ä¡°ü ÂÊÀ¸·Î ±â¿ï¾îÁö°Ô Çϸ鼭 ¼öÆòÀ» À¯Áö½ÃŰ°í ¼ÖÀÇ ¹ÝÀº Ä¡¾Æ¿¡ ±×¸®°í ¹ÝÀº Ä¡Àº¿¡ ÀÖµµ·Ï ÇÑ ´ÙÀ½, ¾ÆÁÖ ÀÛÀº ¿øÀ» ±×¸®´Â µíÇÑ Áøµ¿ ¿îµ¿À» Áָ鼭 ÇÏ´Â ¹æ¹ý. À½½Ä Â±â¿Í Ä¡°£¿¡ ¼ÖÀÌ µé¾î°¡°Ô µÇ¾î ¸¶»çÁö ¿ªÇÒµµ ÇÑ´Ù.
  • Chopper method
    Chopper ¹ý
  • column diffusion method
    ±âµÕ È®»ê ¹æ¹ý
  • combination method
    ¿¬ÇÕ¹ý
    Àη¹À̳ª Ä¡°ü º¸Ã¶ Á¦ÀÛ¿¡¼­ ¸ðÇü»ó¿¡ ³³ÇüÀ» ÀÏÂ÷·Î ¿Ï¼ºÇÏ¿© ±¸°­³»¿¡ ½ÃÀûÇÏ¿© ½Ã°øÇÏ°í ¸Å¸ôÇÏ¿© ÁÖÁ¶ÇÏ¿© ¾ò´Â °£Á¢¹ý°ú Á÷Á¢¹ýÀ» °â¿ëÇÏ´Â ¹æ¹ýÀÌ´Ù.
  • Dehn-Clark`s method
    µ§-Ŭ¶óÅ©¹ý
  • Denis-Leche's method
    µ¥´Ï½º-·¹Ä¡¹ý
    Àü Ȳȭ¹°ÀÇ °ËÃâ¹ýÀ¸·Î, »êÀ» °¡ÇØ ºÎÆÐÇÑ ´Ü¹éÁúÀ» Á¦°ÅÇÏ°í ¿°È­ ¹Ù·ý¿¡ ÀÇÇØ ħÀü °ÇÁ¶½ÃŲ ÈÄ Äª·®ÇÑ´Ù.
  • diffusion method
    È®»ê¹ý
  • direct method
    Á÷Á¢¹ý
    ȯÀÚÀÇ ±¸°­³»¿¡¼­ ¿Î½º Á¶°¢ÇÏ¿© ³³ ¿øÇüÀ» ¾ò¾î ¸Å¸ôÇϰí ÁÖÁ¶ÇÏ¿© Àη¹À̳ª Ä¡°ü º¸Ã¶¹°À» ¾ò´Â ¹æ¹ýÀÌ´Ù.
  • discomfort with this imaging method
    ÃÔ¿µ½Ã ºÒÆí°¨
  • double investing method
    ÀÌÁß ¸Å¸ô¹ý
  • draining method
    ¹è³ó¹ý, È긮´Â ¹æ¹ý
    »óó, ±Ë¾ç, °øµ¿¿¡¼­ ¾×ü³ª ¹è¼³¹°À» ü°èÀûÀ¸·Î ¹èÃâ½ÃŰ´Â °Í.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
multiple endocrine neoplasia (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour.
(type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
Origin: Gr. Plassein = to form
(27 Sep 1997)
multiple endocrine neoplasia 1 <radiology> Multiple endrocrine neoplasia syndrome three P's.
Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH
pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression
Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%).
Synonym: Wermer syndrome
(12 Dec 1998)
multiple endocrine neoplasia 2 <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia
Synonym: Sipple syndrome
(12 Dec 1998)
multiple endocrine neoplasia 3 <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B
Synonym: Schimke, marfanoid syndrome
(12 Dec 1998)
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
multiple endocrine neoplasia type 2 <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
(27 Sep 1997)
multiple endocrine neoplasia type 2a A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands.
(12 Dec 1998)
multiple endocrine neoplasia type 2b A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas.
(12 Dec 1998)
multiple epiphysial dysplasia A dominantly inherited abnormality of epiphyses characterised by difficulty in walking, pain and stiffness of joints, stubby fingers, and often dwarfism of short-limb type; on X-ray examination, the epiphyses are mottled and irregular; ossification centres are late in appearance and may be multiple, but the vertebrae are normal. There is also an autosomal recessive form .
Synonym: dysplasia epiphysialis multiplex.
(05 Mar 2000)
multiple exostosis A disturbance of enchondral bone growth in which multiple, generally benign osteochondromas of long bones appear during childhood, commonly with shortening of the radius and fibula; the ill-effects are usually mechanical but malignant change is rare; autosomal dominant inheritance.
Synonym: diaphysial aclasis, hereditary deforming chondrodystrophy, multiple exostosis, osteochondromatosis.
(05 Mar 2000)
multiple fission Division of the nucleus, simultaneously or successively, into a number of daughter nuclei, followed by division of the cell body into an equal number of parts, each containing a nucleus.
(05 Mar 2000)
multiple fracture Fracture at two or more places in a bone.
See: segmental fracture.
Fracture of several bones occurring simultaneously.
(05 Mar 2000)
multiple gestation <radiology> Incidence: 1% of all births, twins in 1:85; triplets in 1:85x85; etc, uterus large for dates, may have elevated hCG, hPL, and aFP, at risk for IUGR: monochorionic-monoamniotic more than , monochorionic-diamniotic more than , dichorionic-diamniotic findings: 2 placentas indicate dichorionic-diamniotic, 1 placenta indicates monochorionic pregnancy or dichorionic pregnancy with fused placenta, separating membranes confirms diamniotic pregnancy
(12 Dec 1998)
multiple glandular deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple hamartoma syndrome Hypertrichosis and gingival fibromatosis from infancy, accompanied by postpubertal fibroadenomatous breast enlargement; papules of the face are characteristic of multiple trichilemmomas.
Synonym: multiple hamartoma syndrome.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á